Low-dose semaglutide ‘can reduce alcohol cravings’

Library image. Credit: Yui Mok/PA Wire

By Sarah Lowden & PA Media

Initial research has indicated that low-dose semaglutide injections can reduce alcohol craving and some drinking outcomes, prompting calls for a larger clinical trial to evaluate GLP-1RAs for alcohol use disorder.

A clinical trial involving 48 participants found the weekly jab semaglutide, also known as Ozempic and Wegovy, did not affect average drinks per day or the number of days on which they had a drink, but did reduce the amount they drank and their alcohol cravings.